The Association Between the Ct Value of SARS-CoV-2 and the Risk of Death from COVID-19 in Amazonas, Peru, During the Circulation of the Lambda, Gamma, and Delta Variants
- PMID: 40285001
- PMCID: PMC12030881
- DOI: 10.3390/v17040558
The Association Between the Ct Value of SARS-CoV-2 and the Risk of Death from COVID-19 in Amazonas, Peru, During the Circulation of the Lambda, Gamma, and Delta Variants
Abstract
This study aimed to assess the association between the cycle threshold (Ct) values of SARS-CoV-2 and the risk of death from COVID-19 in adult patients from the Amazonas region of Peru during the circulation of the Lambda, Gamma, and Delta variants. The study population included both hospitalized and outpatient patients, symptomatic and asymptomatic, between August 2020 and August 2021. The standardized Ct values of the ORF1ab gene were categorized into low and high Ct groups based on the median Ct value (28.4). Mortality data within 60 days were obtained from the Peruvian epidemiological surveillance system (Notiweb). The risk of death was estimated using Cox regression, adjusting for relevant predictors and potential confounding variables. Among symptomatic COVID-19 patients, no significant difference in the risk of death was observed between those with low and high Ct values (adjusted hazard ratio [aHR] = 1.61; 95% confidence interval [CI], 0.97-2.67; p = 0.067). However, hospitalized patients with low Ct values had a significantly higher risk of death compared to those with high Ct values (aHR = 1.82; 95% CI, 1.06-3.12; p = 0.030). This association persisted after adjusting for age, sex, occupational group, symptom duration, comorbidities, and epidemic dynamics. In conclusion, while Ct values in symptomatic COVID-19 patients (both hospitalized and outpatient) are not associated with a 60-day mortality risk, a low Ct value is linked to an increased risk of death in hospitalized patients.
Keywords: COVID-19; Peru; SARS-CoV-2; cycle threshold (Ct); death; viral load.
Conflict of interest statement
The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Figures




Similar articles
-
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2. Cochrane Database Syst Rev. 2022. Update in: Cochrane Database Syst Rev. 2023 Nov 30;11:CD015395. doi: 10.1002/14651858.CD015395.pub3. PMID: 36126225 Free PMC article. Updated.
-
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD015395. doi: 10.1002/14651858.CD015395.pub3. Cochrane Database Syst Rev. 2023. PMID: 38032024 Free PMC article.
-
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3. Cochrane Database Syst Rev. 2022. PMID: 35866452 Free PMC article.
-
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945. doi: 10.1002/14651858.CD014945.pub2. Cochrane Database Syst Rev. 2022. PMID: 35713300 Free PMC article.
-
Service Interruption in HIV Care Amid COVID-19 Pandemic in Myanmar: Results From Analysis of Routine Program Data 2018-2022.J Int Assoc Provid AIDS Care. 2024 Jan-Dec;23:23259582241299466. doi: 10.1177/23259582241299466. J Int Assoc Provid AIDS Care. 2024. PMID: 39648608 Free PMC article.
References
-
- Author Johns Hopkins University & Medicine. Coronavirus Resource Center. United States of America. 2023. [(accessed on 2 March 2023)]. Available online: https://coronavirus.jhu.edu/map.html.
-
- Costa F. Instituto Nacional de Estadística e Informática. Resultados Definitivos-Amazonas. Perú. [(accessed on 21 June 2021)];2018 Available online: https://www.inei.gob.pe/media/MenuRecursivo/publicaciones_digitales/Est/....
-
- CDC-MINSA, 2022. Sala COVID-19 Perú. Perú. [(accessed on 2 March 2023)];2023 Available online: https://www.dge.gob.pe/covid19.html.
-
- GOREA Sala Situacional COVID-19 Amazonas. Perú. [(accessed on 6 August 2022)];2022 Available online: https://cdn.www.gob.pe/uploads/document/file/2868458/SALA%20SITUACIONAL%....
-
- Campos C.J., Pajuelo-Reyes C., Rojas L.M., De La Cruz-Vargas J.A., Tejedo J.R., Tapia-Limonchi R., Tsukayama P., Chenet S.M. Prevalence of SARS-CoV-2 Variants and Disease Outcome of COVID-19 Patients in the Amazonas Region of Perú. Am. J. Trop. Med. Hyg. 2023;109:523–526. doi: 10.4269/ajtmh.22-0739. - DOI - PMC - PubMed
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous